

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benitzon
Art Unit	1625
Examiner Name	Robin Annette Hylton
Attorney Docket Number	133087.02001

U.S. PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6365602		2002-04-02	Bernstein et al.	
	2	6476077		2002-11-05	Bernstein	
	3	6586432		2003-07-01	Bernstein	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20060241142		2006-10-26	Bernstein et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							<input type="button" value="Remove"/>	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	9807722	WO		1998-02-26	Pfizer		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533834	
Filing Date	2005-10-27	
First Named Inventor	Maria Benktzon	
Art Unit	1625	
Examiner Name	Robin Annette Hyllon	
Attorney Docket Number	133087.02001	

	2	9639383	WO		1996-12-12	Schering Corp.		<input type="checkbox"/>
	3	9825617	WO		1998-06-18	Merck & Co.		<input type="checkbox"/>
	4	0428434	EP		1990-11-06	Sanofi SA		<input type="checkbox"/>
	5	0474561	EP		1998-12-09	Sanofi SA		<input type="checkbox"/>
	6	0515240	EP		1997-09-24	Sanofi		<input type="checkbox"/>
	7	0559638	EP		1993-03-01	Sanofi		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ts
	1	Notice of copending applications.	<input type="checkbox"/>
	2	Gittlin et al., "Psychotropic medications and their effects on sexual function, diagnosis, biology, and treatment approaches," J Clin Psych (1994) 55(9):406-413.	<input type="checkbox"/>
	3	Papp et al., "The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats," Behav Brain Res (2000) 115(1):19-23.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benktzon
Art Unit	1625
Examiner Name	Robin Annette Hyllon
Attorney Docket Number	133087.02001

4	Ryckmans et al., "First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants," <i>Bioorg Med Chem Lett</i> (2002) 12(2):261-264.	<input type="checkbox"/>
5	Santarelli et al., "Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function," <i>Proc Natl Acad Sci</i> (2001) 98(4):1912-1917.	<input type="checkbox"/>
6	Schroeder et al., "FLIPR: a new instrument for accurate, high throughput optical screening," <i>J Biomolecular Screening</i> (1996) 1(2):75-80.	<input type="checkbox"/>
7	Stevenson et al., "4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity," <i>J Med Chem</i> (1998) 41(23):4623-4635.	<input type="checkbox"/>
8	Bernstein et al., "Discovery of novel, orally active dual NK1/NK2 antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> (2001) 11(20):2769-2773.	<input type="checkbox"/>
9	Kenakin et al., "The ligand paradox between affinity and efficacy: can you be there and not make a difference?," <i>TRENDS in Pharmacological Sciences</i> (2002) 23(6):275-280.	<input type="checkbox"/>
10	Rosenzweig-Lipson et al., "Differentiating antidepressants of the future: efficacy and safety," <i>Pharmacology & Therapeutics</i> (2007) 113(1):134-153.	<input type="checkbox"/>
11	McLean 'Do substance P and the NK1 receptor have a role in depression and anxiety?,' <i>Current Pharmaceutical Design</i> (2005) 11(12):1529.	<input type="checkbox"/>
12	Office Action dated September 17, 2007 in copending application no. 10/539,140.	<input type="checkbox"/>
13	Final Office Action dated February 8, 2008 in copending application no. 10/539,140.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10533834
Filing Date	2005-10-27
First Named Inventor	Maria Benktzon
Art Unit	1625
Examiner Name	Robin Annette Hyllon
Attorney Docket Number	133087.02001

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.